[go: up one dir, main page]

WO2008061966A8 - New use of flibanserin - Google Patents

New use of flibanserin

Info

Publication number
WO2008061966A8
WO2008061966A8 PCT/EP2007/062527 EP2007062527W WO2008061966A8 WO 2008061966 A8 WO2008061966 A8 WO 2008061966A8 EP 2007062527 W EP2007062527 W EP 2007062527W WO 2008061966 A8 WO2008061966 A8 WO 2008061966A8
Authority
WO
WIPO (PCT)
Prior art keywords
flibanserin
new use
sub
medicament
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/062527
Other languages
French (fr)
Other versions
WO2008061966A2 (en
WO2008061966A3 (en
Inventor
Angelo Ceci
Marcus Schindler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of WO2008061966A2 publication Critical patent/WO2008061966A2/en
Publication of WO2008061966A3 publication Critical patent/WO2008061966A3/en
Publication of WO2008061966A8 publication Critical patent/WO2008061966A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of flibanserin for preparing a medicament for treating diseases in which the use of therapeutic effective amounts of compounds displaying affinity for the 5-HT<SUB>2B</SUB>-receptor display a therapeutic benefit.
PCT/EP2007/062527 2006-11-22 2007-11-20 New use of flibanserin Ceased WO2008061966A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06124575.9 2006-11-22
EP06124575 2006-11-22

Publications (3)

Publication Number Publication Date
WO2008061966A2 WO2008061966A2 (en) 2008-05-29
WO2008061966A3 WO2008061966A3 (en) 2008-07-10
WO2008061966A8 true WO2008061966A8 (en) 2008-09-04

Family

ID=39201544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/062527 Ceased WO2008061966A2 (en) 2006-11-22 2007-11-20 New use of flibanserin

Country Status (1)

Country Link
WO (1) WO2008061966A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2739489A1 (en) 2008-10-22 2010-04-29 Sam Amer & Co., Inc. Method for treating pulmonary arterial hypertension
CN103467596A (en) * 2012-06-06 2013-12-25 北京大学 Novel target spot for treatment of pulmonary arterial hypertension

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100899297B1 (en) * 2001-08-02 2009-05-26 비다켐 에스. 피. 에이. Stable polymorph of plyvanserine, its technical preparation method and pharmaceutical composition comprising the same
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20060120972A1 (en) * 2004-11-09 2006-06-08 Peter Engels 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension

Also Published As

Publication number Publication date
WO2008061966A2 (en) 2008-05-29
WO2008061966A3 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
MX2008013827A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders.
MX2010014234A (en) Pyrazole compounds 436.
MX2009006704A (en) New compounds.
PH12011502704A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
UA111588C2 (en) JAK INHIBITOR COMPOSITION FOR LOCAL APPLICATION
WO2007131072A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
CL2009000035A1 (en) Derived compounds 3-spiro-heterocyclo-1yl-5h-cyclopentan [d] pyrimidine-indole, useful for inhibiting the activity of akt kinase; pharmaceutical composition comprising said compounds; and use in the treatment of diseases such as cancer, cystic fibrosis, diabetes, Alzheimer&#39;s disease, among others.
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
MX2010003949A (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof.
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
MX2009007337A (en) 5-pyridinone substituted indazoles.
UA103930C2 (en) Normal;heading 1;heading 2;heading 3;COMPOUNDS AND COMPOSITION FOR THE TREATMENT OF PARASITIC DISEASES
WO2009023311A9 (en) Transcutaneous delivery of therapeutic agents
MX2009006327A (en) Heterocycle compounds and methods of use thereof.
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
TW200639156A (en) New compounds
TW200745122A (en) New compounds I
TNSN08506A1 (en) Substituted carboxamides
EA200970849A1 (en) TRICYCLIC DERIVATIVES OF ISOHINOLINE FOR THE TREATMENT OF OBESITY
DE602007007934D1 (en) Imidazoazephinonverbindungen
WO2008061966A8 (en) New use of flibanserin
EP4218786A3 (en) Opiorphin for use as analgesic agent
ECSP088588A (en) USE OF TIOTROPE SALTS IN THE TREATMENT OF PERSISTENT MODERATE ASTHMA
EP2124554A4 (en) Compositions and methods for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07847216

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07847216

Country of ref document: EP

Kind code of ref document: A2